Showcasing cutting-edge products and inaugurating its European flagship store

MILAN, Oct. 13, 2023 /PRNewswire/ — As a global leader in electric two-wheeler transportation and mobility solutions, TAILG will unveil its new TLG brand and its expansion strategies at booth Q02 in Hall 22 at EICMA from 7-12 November, inviting enthusiasts worldwide to participate in the experience.

TAILG Group’s Manufacturing Power

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9213951-tailg-to-unveil-tlg-brand-at-eicma-2023-a-new-era-in-electric-two-wheeled-mobility/

Key highlights will include:

The world’s top manufacturer of electric two-wheelers will announce a new brand strategy TLG for international markets. TLG will debut its new visual identity (VI), underscoring a fusion of innovation and contemporary technological design. A surprise guest and veteran test driver will be onsite to introduce the latest product line-up and share insights from recent test rides. The inauguration and signing event for TLG’s first European flagship store.

During the event, TAILG, a technology group boasting over two decades of R&D and manufacturing expertise in electric two-wheelers, will announces its entry into the European landscape with a comprehensive EV model range.

The TLG brand originates from TAILG, a pioneer in the electric two-wheeler sector. Dedicated to the core innovations of electric two-wheeler mobility, TAILG owns more than 1,000 patents, manages nine intelligent manufacturing facilities in China, and oversees an expansive network of over 30,000 shops worldwide. Their products can be found on the roads of more than 90 countries and regions, solidifying their leadership position in the global market.

Recently, TAILG announced the completion of a world record for the longest electric scooter ride, spanning 94 days and 31,516 kilometers (19,583.6 miles). In a strategic partnership with a Ghana-based company specialized in battery swapping systems, they are set to introduce an electric motorcycle dubbed ‘Jidi’, aiming to reduce rider costs by 30%.

Positioning themselves within the mid-to-premium segment, TLG has engineered a lineup of cutting-edge two-wheelers tailored to regional nuances, rider preferences and distinct market demographics. These offerings aim to furnish European riders with a superior, low-carbon and eco-conscious short-distance commuting experience. The entire range will be showcased at EICMA.

As a world trendsetter in the two-wheeler arena, it is crucial for TAILG to debut its new TLG brand at EICMA. The international market has seen exponential growth in recent years, especially in Europe, led by Germany, France, Italy and the Netherlands. Recognizing the momentum, TAILG opted to inaugurate the new brand’s European flagship store in Switzerland, a hub for many of the world’s prestigious brands. The move aims to anchor a robust foothold for the new brand in Europe, emphasizing the continent’s vast market potential and paving the way for accelerated channel expansion.

The 400-square-meter flagship store, once completed, will be the premier European venue where enthusiasts can directly engage with newly launched TLG offering. "We welcome anyone interested in two-wheel mobility to join us at the booth or store and immerse themselves in the allure of our modern, youthful, and tech-savvy brand," said Li Kunfeng, Vice President of TAILG’s overseas business.

About TAILG

Founded in 2004 in Shenzhen, China, TAILG is a global technology group company which integrates the research and development, production, sales, sharing, charging, and battery-swapping of electric vehicles, and other whole industry chain services. TAILG owns more than 1,000 national patents and operates nine production bases in China and has an annual production capacity of over 12 million vehicles. It also has more than 30,000 terminal experience stores and exports to more than 90 countries and regions worldwide.

For more information, please visit https://www.tailg.com/

TAILG’s long ranger battery-powered two-wheeler won the Guinness World Records honour of longest journey on an electric scoote" with a range of 31,516km.

https://static.prnasia.com/pro/fec/jwplayer-7.12.1/jwplayer.js jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”   jwplayer(‘myplayer1’).setup({file: ‘https://mma.prnasia.com/media2/2246536/Video_1.mp4’, image: ‘https://mma.prnasia.com/media2/2246536/Video_1.mp4?p=medium’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’}); https://static.prnasia.com/pro/fec/jwplayer-7.12.1/jwplayer.js jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”   jwplayer(‘myplayer2’).setup({file: ‘https://mma.prnasia.com/media2/2246540/Video_2.mp4’, image: ‘https://mma.prnasia.com/media2/2246540/Video_2.mp4?p=medium’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’}); https://static.prnasia.com/pro/fec/jwplayer-7.12.1/jwplayer.js jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”   jwplayer(‘myplayer3’).setup({file: ‘https://mma.prnasia.com/media2/2246537/Video_3.mp4’, image: ‘https://mma.prnasia.com/media2/2246537/Video_3.mp4?p=medium’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’});

Source : TAILG to Unveil TLG Brand at EICMA 2023: A New Era in Electric Two-Wheeled Mobility

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

DUBAI, UAE, Oct. 13, 2023 /PRNewswire/ — During UBBF 2023, Richard Jin, President of Huawei Optical Business Product Line, delivered a keynote speech entitled "Bring F5.5G to Reality: Milestones on Our Way to Intelligent World". In the speech, Richard proposed the concept of three-phase network construction for the first time. Specifically, there are three driving forces for network development, that is, video (100Mbps network), experience (1Gbps network), and intelligence (10Gbps network). Against this backdrop, Huawei launched the F5.5G-oriented three-phase all-optical target network architecture — all-optical coverage for 100Mbps home broadband, all-optical connections extending 1Gbps to each room, and all-optical computing for 10Gbps Everywhere. The three-phase construction of the all-optical target network can meet the network connection requirements of hot services in each phase, bringing F5.5G into reality and striding towards an intelligent world.

Richard Jin delivering his keynote speech at UBBF 2023

Phase 1: Video-Driven, All-Optical Coverage for 100Mbps Home Broadband

With the continuous improvement of video resolution and the rapid popularization of video interaction and immersive XR, the bandwidth is upgraded from 10 Mbps to 100 Mbps and 1000 Mbps. In this phase, HD video and video interaction become the major driving force to realize the goal of building an all-optical network with a 100 Mbps home broadband rate. Operators need to fully move towards FMC, and replace cooper lines and cables with FTTH all-optical network. Serialized AirPON can accelerate FTTH construction and support GPON and 10G PON compatibility, enabling rapid provision of gigabit services in hotspot areas. Meanwhile, operators need to deploy OTN to metro aggregation layer, and build 3D-mesh 400G ready backbone networks, supporting non-blocking bandwidth and zero video lagging. Typical technological innovations in this phase include FlexPON, DQ ODN, and high-performance 400G.

Phase 2: Experience-Driven, All-Optical Connections Extending 1Gbps to Rooms

With increasingly diversified digital applications, fibers are extended from living rooms to bedrooms, studies, and kitchens, enabling click-and-start applications and delivering an immersive network experience. All these developments pose higher requirements on network coverage, bandwidth, latency, and roaming. In this phase, users are willing to pay for a more premium home network experience. Therefore, End-to-end (E2E) service experience assurance becomes the key to achieving the goal of all-optical connections and 1 Gbps extending to each room. Operators need to upgrade 10G PON to fully deliver gigabit services, introduce fiber-to-the-room (FTTR), metro 100G OTN to CO, backbone 400G non-blocking ultra-broadband. Typical technological innovations in this phase are FTTR, metro pooling WDM, and the intelligent network management and control system.

Phase 3: Intelligence-Driven, All-Optical Computing for 10Gbps Everywhere

AI accelerates content manufacturing and promotes the intelligent transformation of industries. To cope with traffic surges and migration of massive data to the cloud, a computing-centric network is required to provide bus-level connection capabilities. Similar to the CPU, bus, and accessories of a computer, the computing power and storage of the data center (DC) need to exchange information with end-users in real time through a high-performance network to achieve the goal of all-optical computing for 10Gbps Everywhere.

In this phase, the FTTR-based all-optical home bus supports connect-and-play of IoT devices and integrates connection, sensing, computing, and storage capabilities for 10Gbps throughout the house. In addition, the all-optical cloud bus based on 50G PON and 800G OTN implements all-optical one-hop user-DC or DC-DC connections. Typical technological innovations in this phase include 50G PON, metro OTN completely to CO, and backbone 800G. In addition, OTN needs to be designed for DC scenarios. Upon this, Huawei launched Kepler, the next-generation OTN platform, delivering more than 100T single-subrack switching capacity. Leveraging new materials and structures, Kepler reduces power consumption per Gbit by 65%, and the power usage effectiveness (PUE) to 1.2. It also provides intelligent computing units to comprehensively improve connection efficiency.

The three-phase all-optical target network can ensure parallel evolution and smooth upgrade from F5G to F5.5G. According to Richard, "Operators need the most appropriate all-optical target network construction solution in different development phases. So far, 100Mbps has changed the content, 1Gbps is changing the broadband experience, and 10Gbps will change society. Let’s work together to bring F5.5G into reality and stride towards an intelligent world."

Source : Huawei Launches the F5.5G-Oriented All-Optical Target Network Architecture for Three Phases

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHENZHEN, China, Oct. 13, 2023 /PRNewswire/ — On October 1, Shenzhen Longsys Electronics Co., Ltd.(301308.SZ) (hereinafter referred to as "Longsys") acquired a 70% equity stake in Powertech Technology (Suzhou) Limited. The transaction has been officially completed and will be included in the consolidated statements of Longsys from now on.

Powertech Technology (Suzhou) Limited has been rebranded as Longforce (Suzhou) Limited (hereinafter referred to as "Longforce"), and will be directly controlled by Longsys Electronics (Suzhou) Co., Ltd., a new wholly-owned subsidiary of Longsys.

Powertech Technology Inc. (PTI) and its affiliated companies remain dedicated to providing unwavering support, as per the service agreement signed, to ensure the continued operation of Longforce.

Longforce, formerly known as Spansion, became a wholly-owned subsidiary of PTI in 2009. Its main services cover chip packaging, testing, and SMT, and its main products include flash memory chips, memory chips, and logic chips.

With the successful conclusion of this transaction, Longforce is now prepared to operate autonomously and committed to servicing its existing clientele in the packaging and testing sphere. Notably, Longforce is embarking on a journey of increased investment in R&D and packaging & testing processes, active introduction of state-of-the-art packaging testing equipment and top talents from the industry, and continuous improvement of packaging and testing capabilities to establish a high-end packaging testing hub. Longforce is dedicated to providing top-tier services to clients across various sectors, such as artificial intelligence, high-performance computing, smart vehicles, smartphones, and wearables.

In addition, this acquisition stands as a pivotal move by Longsys to fortify its manufacturing footprint. It envisions substantial enhancements to its storage chip packaging and testing capabilities, optimized capacity utilization, perfection of its industrial chain layout, and strengthened business collaboration with storage wafer foundries. This multifaceted approach extends to enhancing product quality, ensuring rapid response to customer needs, tailoring product specifications to meet market demands, and maintaining a steady production capacity. Collectively, these initiatives will significantly bolster the company’s market presence, core competitiveness, and ultimately elevate long-term profitability, aligning seamlessly with the company’s overarching strategy in the realm of semiconductor storage brands.

It’s worth highlighting that the company has consistently underscored the importance of a global presence for its storage business. Active implementation of a domestic-international dual circulation has been at the heart of its operations. Since the cross-border acquisition of Lexar in 2017 and global operational success, the company has continually explored ways to enhance international operation capabilities, create a flexible supply chain, develop a robust business system, and more. Leveraging its proximity to local customers, proprietary technologies, comprehensive storage product offerings, and local manufacturing advantages, its commitment in delivering premium services to its esteemed global clientele remains steadfast.

This year, the company has made groundbreaking achievements with self-developed main control chips. When combined with its advanced packaging and testing capabilities, these breakthroughs will empower its core storage products comprehensively, effectively enhance product quality, performance, and security across all product lines, and further solidify its core competitiveness within the storage sector.

Source : Strengthening the Industry Chain Layout: Longsys Successfully Acquires a 70% Equity Stake in Longforce

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BEIJING, Oct. 13, 2023 /PRNewswire/ — A news report from chinadaily.com.cn:

https://static.prnasia.com/pro/fec/jwplayer-7.12.1/jwplayer.js jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”   jwplayer(‘myplayer1’).setup({file: ‘https://mma.prnasia.com/media2/2246398/20231012.mp4’, image: ‘https://mma.prnasia.com/media2/2246398/20231012.mp4?p=medium’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’});

This year marks the 10th anniversary of the Belt and Road Initiative (BRI). As the first public service project under the BRI in Papua New Guinea (PNG), the Butuka Academy is the largest multi-functional school with the most advanced facilities in the South Pacific island countries. It provides more than 3,000 primary and secondary school students with access to education. The school also serves as a bridge for cultural exchanges between China and PNG. Over the past decade, the BRI has achieved fruitful results and has become a popular international public good and a platform for international cooperation.

Watch the video to find out more.

 A production of Qiushi Online (en.qstheory.cn) 

Source : Butuka Academy: A Witness of the Friendship Along the "Belt and Road"

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases

SYDNEY, Oct. 13, 2023 /PRNewswire/ — Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay will conduct a series of meetings at the BIO Investor Forum, San Francisco on October 17-18, 2023.  The following week, Dr Gourlay and CMO Dr Dana Hilt will participate in the 16th annual CTAD conference in Boston where they will present a scientific poster on October 25 and conduct a number of stakeholders meetings.

Dr Gourlay and Dr Hilt will be discussing progress made with the Company’s two ongoing Phase 2 trials:

XanaCIDD Phase 2a trial in patients with cognitive impairment and major depressive disorder

Enrolment continues in the XanaCIDD Phase 2a proof-of-concept trial in 160 patients with cognitive impairment associated with persistent Major Depressive Disorder (MDD). Cognitive impairment is common in MDD and currently there are no anti-depressant drugs approved for its treatment, although some companies have reported trials to assess effects of their anti-depressants on cognition. Consequently, there is a high unmet need for novel and safe treatments for this indication.

The trial is being conducted in Australia, the UK and the USA. It is treating patients with 10 mg of Xanamem or placebo once daily for six weeks as monotherapy or added to stable background anti-depressant therapy. The primary endpoint is an attention composite of three computerized cognitive tests measuring attention and working memory. Depression is assessed as a key secondary endpoint using the MADRS scale.

The trial is expected to report results in the first half of 2024.

XanaMIA Phase 2b trial in patients with mild-moderate Alzheimer’s Disease (AD)

On 26 September Actinogen announced that it had redesigned operational features of the XanaMIA Phase 2b clinical trial of Xanamem in patients with mild to moderate AD to reduce the cost and time to initial results.

Key features of the revised XanaMIA Phase 2b trial:

The trial will enrol patients with an elevated blood pTau biomarker (the same group shown to have a large Xanamem clinical effect in the previous Phase 2a biomarker trial) and keeps the same endpoints and 36‑week treatment length. The removal of the 5mg dose arm reduces patient numbers by one-third to 220 patients, who will receive either 10mg or placebo daily Enrolment of the first 100 patients will take place at Australian sites and initial efficacy and safety results from an administrative interim analysis will occur when approximately 100 patients reach 24 weeks of treatment, expected in the first half of 2025 Collectively, these changes reduce trial costs significantly and increase forecast receipts from Australian R&D tax incentive cash refunds by focusing on Australian R&D activities in the near term. Net forecast savings between now and June 2025 will be in the order of A$30 million compared to the original plan The XanaMIA Phase 2b trial will finalize Australian clinical site start up activities as soon as possible, with site activation expected before the end of the year Final results are anticipated in the second half of 2025.

Dr Steven Gourlay, Actinogen CEO and MD, commented:

"Actinogen is at an important juncture in the world of drug development with its promising oral therapy Xanamem. While recent positive data on new amyloid antibody infusions give Alzheimer’s patients hope, they do not halt disease progression, highlighting the continued and urgent need to find effective and safe non-amyloid therapies to arrest cognitive decline.

"Our high quality randomized XanaMIA Phase 2b trial will be conducted in 220 patients with mild-moderate AD who are biomarker-positive and thus likely to have progressive disease.  We will finalize Australian clinical site start up activities as soon as possible, with site activation expected before the end of the calendar year.

"Our XanaCIDD Phase 2a trial assessing the effects of Xanamem on cognition and depression represents a novel and important approach towards treating patients with MDD with the hope that the therapy will be rapidly acting on cognition, as we have seen in two prior trials in cognitively normal people, and also have effects on depression itself."

For further information:

Dr. Steven Gourlay 

Michael Roberts     

CEO & Managing Director 

Investor Relations  

P: +61 2 8964 7401   

M: +61 423 866 231  

E. [email protected]

E. [email protected]  

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, attention, reasoning, awareness and decision-making.

Actinogen is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer’s Disease and Depression and hopes to study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impact in these and many other diseases. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

Current and Upcoming Clinical Trials

The XanaCIDD Phase 2a depression trial is a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 160 patients. Patients are evenly randomized to receive Xanamem 10 mg once daily or placebo, in some cases in addition to their existing antidepressant therapy, and effects on cognition and depression are assessed.

The XanaMIA Phase 2b Alzheimer’s disease trial is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 220 patients with mild to moderate AD and progressive disease, determined by clinical criteria and confirmed by an elevated level of the pTau181 protein biomarker in blood. Patients receive Xanamem 10 mg or placebo, once daily, and effects on cognition, function and progression of Alzheimer’s disease are assessed. Thus, Xanamem is being assessed in this trial for its potential effects as a both a cognitive enhancer and a disease course modifier.

About Xanamem

Xanamem’s novel mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease and excess cortisol is known to be toxic to brain cells. Cognitive impairment is also a feature in Depression and many other diseases. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials.

The Company has studied 11β-HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in functional and cognitive ability in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterize Xanamem’s therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered "at-risk statements" – not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised.

®  Xanamem is a registered trademark of Actinogen Medical Limited

Source : Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD) An interim data readout in AA is expected in Q3 2024

SAN DIEGO, Oct. 13, 2023 /PRNewswire/ — Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a global multicenter Phase 2a study of IMG-007 in adult patients with AA. The study will evaluate the safety, efficacy, pharmacokinetics, and biomarkers of IMG-007 in AA patients with 50% or greater scalp hair loss. More information about the study can be found here NCT06060977.

"Alopecia areata is a devastating disease which affects approximately 147 million people globally. Currently, there are limited treatment options and no approved biologics for AA. Better treatment options are needed," said Jonathan Wang, Ph.D., Chief Executive Officer of Inmagene. "IMG-007 could potentially provide a safe and effective biologic therapy with once every 12 weeks dosing regimen for AA patients."

IMG-007 is a humanized IgG1 mAb that specifically binds to the OX40 receptor and potently blocks the signaling between OX40 and its ligand. IMG-007 has been engineered to have an extended half-life to allow less frequent dosing and a silenced antibody-dependent cell-mediated cytotoxicity (ADCC) function to reduce safety risks.  In a Phase 1 study in healthy adult participants, IMG-007 has demonstrated a favorable safety profile, without any reports of pyrexia or chills. A single treatment of IMG-007 at projected therapeutic dose levels maintained the target exposure for 12 to 18 weeks, which may allow IMG-007 for every 12 weeks administration.

In addition to the global Phase 2a study in AA patients, IMG-007 is also being evaluated in a global Phase 2a study in adult patients with AD with an interim data readout expected in Q2 2024.

About Inmagene

Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunological and inflammatory diseases. It has four clinical-stage drug candidates. The lead compound, IMG-007, an OX40 antagonist mAb with an extended half-life and a silenced ADCC function, is in two global Phase 2a clinical trials. IMG-004, a non-covalent, reversible BTK inhibitor, which has demonstrated a more durable pharmacodynamic effect and longer half-life than most leading BTK inhibitors, is completing Phase 1 clinical development. IMG-008, a long-acting anti-IL-36R mAb with a longer half-life and higher exposure than an approved IL-36R antagonist, is entering global Phase 1 clinical development. Moreover, IMG-020 (izokibep), an anti-IL-17 small protein therapeutic, is in global clinical development for 5 indications, including 2 pivotal trials, in collaboration with global partners. 

Based on its proprietary QuadraTek® platform, Inmagene discovers and develops novel drug candidates. Inmagene has out-licensed IMG-018, a differentiated anti-ILT7 mAb drug candidate, to establish a new drug development company Celexor Bio, in collaboration with Aditum Bio. Inmagene has formed strategic partnerships with multiple partners, such as HUTCHMED and Affibody AB, to develop highly innovative drug candidates.

About IMG-007

IMG-007 is a humanized IgG1 mAb specifically binds to OX40, a co-stimulatory receptor that is present primarily on activated T cells. OX40-OX40L axis is important in T cell activation, expansion, and survival, thereby having an important role in the pathogenesis of a spectrum of immunological and inflammatory diseases. In nonclinical studies, IMG-007 potently blocks the signaling between OX40 and OX40L. IMG-007 was discovered by HUTCHMED, with Inmagene assuming global development responsibility at the candidate stage. Inmagene owns global rights for IMG-007.

About Alopecia Areata

Alopecia areata is a chronic autoimmune disease characterized by nonscarring hair loss involving the scalp, face, and/or body. It can affect people of all ages. Approximately 2% of the general population can be affected by AA during their lifetime1,2.  Approximately 43% of AA patients have over 50% hair loss3. AA significantly impacts patients’ daily life and often leads to profound psychological distress, social isolation, anxiety, and depression. The immunopathogenesis of AA and AD largely overlaps, and AA and AD coexist in many patients4,5.

Forward-Looking Statements

This press release contains forward-looking statements. While Inmagene believes the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

1Pratt CH, King LE Jr, Messenger AG, et al. Nat Rev Dis Primers 2017;3:17011.

2Mirzoyev1 SA, Schrum AG, Davis M, et al. J Invest Dermatol. 2014;134(4):1141–1142.

3Benigno M, Anastassopoulos KP, Mostaghimi A, et al. Clin Cosmetic Invest Dermatol. 2020;13:259–266.

4Kageyama R, Ito T, Hanai S, et al. Int. J Mol Sci 2021;22(5):2618.

5Kridin K, Renert-Yuval Y, Guttman-Yassky E, et al. J Allergy Clin Immunol Pract 2020,8(4):1323-1328.

Media
For inquiries, please contact:
Anna Vardanyan 
public.relations@inmagenebio.com 

Source : Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BEIJING, Oct. 13, 2023 /PRNewswire/ — WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it developed a personalized video recommendation system based on deep learning according to the development needs of the industry, providing new ideas and directions for the research of personalized video recommendation under deep learning.

The underlying technical logic of WiMi’s deep learning-based personalized video recommendation system mainly includes the construction of neural network models, feature representation learning, model training and optimization, fusion of contextual information, real-time recommendation and online learning, and the interpretation and interpretability of recommendation results. The application of these technologies can improve the accuracy, degree of personalization, and user experience of the recommendation algorithm and provide users with better video recommendation services:

Neural network models: At the heart of deep learning are neural network models. In personalized video recommendation, different types of neural network models are used to model the association between the user and the video. Neural network models include Convolutional Neural Networks (CNN), Recurrent Neural Networks (RNN), and Long Short Term Memory Networks (LSTM). These models are able to perform nonlinear transformations and feature extraction through multiple layers of neuronal units to better capture the hidden associations between users and video content.

Feature Representation Learning: In a personalized video recommendation system, effective feature representations are critical to the performance of the model. While traditional recommendation algorithms require features to be more programmatic and modular, deep learning-based approaches can automatically learn feature representations. By introducing structures such as the embedding layer or convolutional layer in neural networks, user and video features can be transformed into low-dimensional dense vectors to better capture their interactions.

Model training and optimization: Deep learning models are usually trained using optimization algorithms such as gradient descent to minimize prediction errors. In personalized video recommendation, optimization algorithms such as stochastic gradient descent (SGD) or Adam are used to update model parameters. To improve the generalization ability of the model and prevent over-fitting, regularization techniques are used. Meanwhile, methods such as batch training or mini-batch training are used to accelerate the training process of the model.

Fusion of contextual information: In personalized video recommendation, the user’s interest and preference may be influenced by contextual information, such as time, location, device, etc. To make recommendations more accurate, contextual information is incorporated into deep learning models. An attention mechanism is used to dynamically adjust the weights between user and video features to reflect the current contextual information.

Real-time recommendation and online learning: Personalized video recommendation needs to respond to user requests in real-time and make recommendations based on real-time behavioral data. Through online learning methods, the model is constantly updated and optimized to adapt to the real-time changes of users. Online learning is achieved through techniques such as incremental training or incremental updating incremental updating, so that the model can obtain the latest user behavioral data in time and make real-time adjustments and optimizations to the model.

Recommendation result interpretation and interpretability: In personalized video recommendation, the user’s interpretation and interpretability of the recommendation result are very important. In order to increase the interpretability of the recommendation results, techniques such as the attention mechanism and the inference mechanism to explain the generative model are used so as to explain the basis and reasons for the recommendation results to the user. It improves the user’s understanding and acceptance of the recommendation results and enhances the user’s trust and satisfaction.

A practical application of WiMi’s deep learning-based personalized video recommendation system. The core of the system is the recommendation module, which uses deep learning models to model user interests and generate personalized video recommendation results. In practical applications, other techniques and algorithms, such as content-based recommendation and social network analysis, can be combined to further improve the accuracy and diversity of personalized video recommendations. In addition, user feedback can be used to continuously optimize and update the recommendation model to meet the changing interests and needs of users.

WiMi’s deep learning-based personalized video recommendation technology solves information overload, personalizes user needs, improves user experience, and promotes market development in the online video industry. With the continuous progress of artificial intelligence and deep learning technology, personalized video recommendation technology can also be combined with other emerging technologies to develop more application directions. For example, combined with augmented learning technology, the recommendation system can further optimize the recommendation strategy through interactive learning with users; combined with virtual reality and augmented reality technology, the recommendation system can provide a more immersive video viewing experience. Personalized video recommendation technology can be combined with social media and user participation to provide a richer user experience. By analyzing users’ social network information and interactive behaviors, the recommendation system can recommend videos related to their interests and promote communication and sharing among users. This model of social interaction and user participation can increase user stickiness and loyalty, and drive users to generate more content and spread word-of-mouth.

About WIMI Hologram Cloud

WIMI Hologram Cloud, Inc. (NASDAQ:WIMI) is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, 3D holographic pulse LiDAR, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation and others. Its services and holographic AR technologies include holographic AR automotive application, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, interactive holographic communication and other holographic AR technologies.

Safe Harbor Statements

This press release contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release and the Company’s strategic and operational plans contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the US Securities and Exchange Commission ("SEC") on Forms 20−F and 6−K, in its annual report to shareholders, in press releases, and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, financial condition, and results of operations; the expected growth of the AR holographic industry; and the Company’s expectations regarding demand for and market acceptance of its products and services.

Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and the current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release. The Company does not undertake any obligation to update any forward-looking statement except as required under applicable laws.

Source : WiMi Developed a Deep Learning-Based Approach to Personalized Video Recommendations

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network